Capital Advisors Ltd’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Capital Advisors Ltd's CGEM Position: Q3 2026 in Review
Capital Advisors Ltd held its Cullinan Therapeutics (CGEM) position steady in Q3 2026 at 1,600 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #651.
Capital Advisors Ltd first reported a position in CGEM in Q2 2022 and has held it in 9 quarters since. The position peaked at $29K in Q2 2026. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Capital Advisors Ltd held 1,600 shares of Cullinan Therapeutics worth $25K as of Q3 2026.
- Capital Advisors Ltd left its Cullinan Therapeutics share count unchanged in Q3 2026.
- Cullinan Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q3 2026, its #651 holding.
- Capital Advisors Ltd first reported a position in Cullinan Therapeutics in Q2 2022 and has held it in 9 quarters since.
- Capital Advisors Ltd's Cullinan Therapeutics position peaked at $29K in Q2 2026.
- 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Capital Advisors Ltd's 13F filing for Q3 2026, filed 27 Oct 2026.